<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105776</url>
  </required_header>
  <id_info>
    <org_study_id>CNS_PD_001</org_study_id>
    <nct_id>NCT05105776</nct_id>
  </id_info>
  <brief_title>Multimodal Neuromodulation in Individuals With Parkinson's Disease</brief_title>
  <official_title>Multimodal Neuromodulation in Individuals With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryan D'Arcy</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Parkinson's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthTech Connex Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multimodal non-invasive neuromodulation paired with physical therapy is a promising treatment&#xD;
      modality for Parkinson's Disease (&quot;PD&quot;), however the optimal stimulation method, dose, and&#xD;
      associated therapeutic protocol for long-lasting clinical benefits have not yet been&#xD;
      identified for this population.&#xD;
&#xD;
      Here the investigators aim to develop and execute a preliminary clinical study exploring the&#xD;
      potential benefits of multimodal non-invasive neuromodulation. The therapeutic intervention&#xD;
      will involve translingual neurostimulation +/- galvanic neurostimulation, paired with an&#xD;
      intensive physical and cognitive therapy program.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">June 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Galvanic stimulation is masked (sham vs active)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>NeuroCom Sensory Organization Test (SOT)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Composite balance score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NeuroCom Limits of Stability test (LOS)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Postural stability score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NeuroCom Adaptation Test</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Adaptation score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MiniBESTest</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Balance score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography - amplitudes</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Measured with NeuroCatch Platform 2 (NCP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalography - latencies</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Measured with NeuroCatch Platform 2 (NCP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Part II and part III: Motor function score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>Baseline to week 4</time_frame>
    <description>Cognitive test; total score</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Physiotherapy only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physiotherapy + translingual neurostimulation provided throughout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham GVS (week 1) to active GVS (week 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physiotherapy + translingual neurostimulation provided throughout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active GVS throughout weeks 1 + 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physiotherapy + translingual neurostimulation provided throughout</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Galvanic stimulation</intervention_name>
    <description>Galvanic stimulation during physiotherapy sessions</description>
    <arm_group_label>Active GVS throughout weeks 1 + 2</arm_group_label>
    <arm_group_label>Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)</arm_group_label>
    <arm_group_label>Sham GVS (week 1) to active GVS (week 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A diagnosis of idiopathic PD&#xD;
&#xD;
          2. Disease staging between II and III (mild to moderate), according to the modified Hoehn&#xD;
             and Yahr scale;&#xD;
&#xD;
          3. Currently taking prescribed antiparkinsonian medication regularly with:&#xD;
&#xD;
          4. No medication changes in the last 30 days&#xD;
&#xD;
          5. Responsive to oral dopamine replacement therapy&#xD;
&#xD;
          6. Score higher than 24, verified through the Montreal Cognitive Assessment33.&#xD;
&#xD;
          7. Must demonstrate moderate burden of motor symptoms (MDS-UPDRS part II &gt;12 and&#xD;
             MDS-UPDRS part III scores &gt;35) 34&#xD;
&#xD;
          8. Must be able to voluntarily give written (or verbal) informed consent&#xD;
&#xD;
          9. Must have ability to reliably use the devices&#xD;
&#xD;
         10. Must be able to understand and complete all assessments (provided in English only)&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         11. Diagnosis of atypical parkinsonism;&#xD;
&#xD;
         12. History of epilepsy&#xD;
&#xD;
         13. Presence of an implanted electrical device&#xD;
&#xD;
         14. Previous surgical intervention for PD (DBS implantation - deep brain stimulation);&#xD;
&#xD;
         15. Treated with a pump for continuous delivery of DRT (Dopamine replacement therapy)&#xD;
&#xD;
         16. Presence of severe freezing episodes.&#xD;
&#xD;
         17. Women who are pregnant or nursing&#xD;
&#xD;
         18. History of unstable mood disorder or unstable anxiety disorder or psychosis&#xD;
&#xD;
         19. Those with a recent history of substance abuse and/or dependence (alcohol or other&#xD;
             drugs)&#xD;
&#xD;
         20. Have been diagnosed with neurological disease other than Parkinson's disease.&#xD;
&#xD;
         21. Have a major concomitant illness or illnesses including cancer or disease of the&#xD;
             cardiovascular, respiratory and/or renal systems deemed significant medical risk in&#xD;
             the opinion of the principle investigator&#xD;
&#xD;
         22. Have a diagnosed vestibular dysfunction&#xD;
&#xD;
         23. Have had eye surgery within the previous three months or ear surgery within the&#xD;
             previous six months&#xD;
&#xD;
         24. Have participated in another clinical trial within the last 30 days or are currently&#xD;
             enrolled in another interventional clinical trial&#xD;
&#xD;
         25. Contraindicated for PoNS, including:&#xD;
&#xD;
             25.1. Current disease or sensitivity of the oral cavity 25.2. History of oral cancer&#xD;
             25.3. Oral surgery within three months of screening 25.4. Oral cavity piercings that&#xD;
             could interfere with PoNSTM use 25.5. Sensitivity to Nickel, Copper, or Gold 25.6.&#xD;
             Currently enrolled in a PoNSTM treatment program or use of the PoNSTM device in the&#xD;
             last 5 weeks 25.7. History of penetrating brain injuries 25.8. Chronic infectious&#xD;
             disease 25.9. Unmanaged hypertension 25.10. Diabetes 25.11. History of seizures&#xD;
&#xD;
         26. Contraindicated for GVS, including:&#xD;
&#xD;
        26.1. Metallic brain implant(s) 26.2. Brain surgery within the past six months 26.3. Highly&#xD;
        sensitive skin behind the ears&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natasha Campbell</last_name>
    <phone>778-874-7758</phone>
    <email>natashacampbell@healthtechconnex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Neurology Studies</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Natasha Campbell</last_name>
      <phone>778-874-7758</phone>
      <email>natashacampbell@healthtechconnex.com</email>
    </contact>
    <investigator>
      <last_name>Ryan D'Arcy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin McKeown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>HealthTech Connex Inc.</investigator_affiliation>
    <investigator_full_name>Ryan D'Arcy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

